Showing 4281-4290 of 7011 results for "".
- ADorable-1 Trial Meets Endpoints for EBGLYSS in Children With Atopic Dermatitishttps://reachmd.com/news/adorable-1-trial-meets-endpoints-for-ebglyss-in-children-with-atopic-dermatitis/2486087/Eli Lilly and Company announced positive topline results from the phase 3 ADorable-1 trial of lebrikizumab-lbkz (Ebglyss) in pediatric patients aged 6 months to 18 years with moderate-to-severe atopic dermatitis (AD), showing the therapy meeting its primary and sec
- FDA Expands Secukinumab to Adolescents With Moderate to Severe HShttps://reachmd.com/news/fda-expands-secukinumab-to-adolescents-with-moderate-to-severe-hs/2486084/The US Food and Drug Administrationv (FDA) has approved secukinumab (Cosentyx, Novartis) for pediatric patients aged 12 years and older with moderate to severe hidradenitis suppurativa (HS), becoming the only IL-17A inhibitor approved for this group, according to a
- Survey: One-Third of US Adults Made Financial Tradeoffs for Healthcarehttps://reachmd.com/news/survey-one-third-of-us-adults-made-financial-tradeoffs-for-healthcare/2486049/About one in three U.S. adults—equivalent to more than 82 million people—reported making at least one “daily life trade-off” in the prior year to pay for healthcare expenses, according to a
- Comparative Outcomes of Fluticasone‑Based vs Budesonide Dual Inhalers in COPDhttps://reachmd.com/news/comparative-outcomes-of-fluticasonebased-vs-budesonide-dual-inhalers-in-copd/2486037/Investigators reported comparative outcomes among US adults aged 40 years or older with chronic obstructive pulmonary disease (COPD) who initiated one of three inhaled corticosteroid–long-acting β-agonist (ICS–LABA) single-inhaler products in
- INTEGUMENT-OLE Data Show Sustained Efficacy of Roflumilast in Early Childhood ADhttps://reachmd.com/news/integument-ole-data-show-sustained-efficacy-of-roflumilast-in-early-childhood-ad/2486045/The 56-week phase 3 open-label extension for the INTEGUMENT trial (INTEGUMETN-OLE) indicated once-daily roflumilast cream 0.05% maintained efficacy and demonstrated favorable long-term safety in children aged 2 to 5 years with mild-to-moderate atopic dermatitis (AD
- GLP‑1RA Switching and Treatment Persistence in Adults Without Diabeteshttps://reachmd.com/news/glp1ra-switching-and-treatment-persistence-in-adults-without-diabetes/2486029/Real-world use of GLP-1 receptor agonists for weight management among adults without diabetes was described as non-linear, with medication changes and limited one-year continuation in an insurance-claims dataset. In a recent report on
- Habitual Activity and Executive Function in Adolescents: Longitudinal Wearable Studyhttps://reachmd.com/news/habitual-activity-and-executive-function-in-adolescents-longitudinal-wearable-study/2485987/Across one academic year in secondary-school students, investigators reported that higher physical activity (steps/day) was associated with better perfor
- Median HbA1c by Age and Sex: Temporal Cohort Findings (2012–2024)https://reachmd.com/news/median-hba1c-by-age-and-sex-temporal-cohort-findings-20122024/2486015/Findings from three cross-sectional cohorts (2012, 2017, 2024) in Catanzaro, Southern Italy, were reported as showing broadly stable population-level median HbA1c over a 12-year span, alongside age
- Cardiometabolic Outcomes After Fibroid Surgery: Hysterectomy vs Uterine Preservationhttps://reachmd.com/news/cardiometabolic-outcomes-after-fibroid-surgery-hysterectomy-vs-uterine-preservation/2485928/A retrospective analysis of U.S. administrative claims examined whether 10-year cardiometabolic diagnoses differed by management approach among privately insured women w
- ICU Acinetobacter in Romania: High Carbapenem Non-Susceptibility, Delayed Active Therapyhttps://reachmd.com/news/icu-acinetobacter-in-romania-high-carbapenem-non-susceptibility-delayed-active-therapy/2485929/A six-year, single-center intensive care unit cohort from Romania describes an endemic Acinetobacter ecology marked by predominance of Acinetobacter baumannii, e